Earnings Releases·Nov 13, 2026, 9:25 AM ET

Lifeward — Third Quarter 2026 Earnings Summary

Total revenue declined 12% year-over-year to $5.4 million, driven by a 43% drop in ReWalk Personal revenue to $1.7 million due to the transition to a channel-partner model, partially offset by an 18% increase in AlterG revenue to $3.6 million.
Net loss widened to $5.1 million ($1.32 per share) from $3.2 million in the prior-year quarter, while gross margin contracted to 27.4% from 43.7% due to foreign exchange fluctuations, higher freight costs, tariffs, and Oratech acquisition expenses.
The company is executing a strategic pivot for ReWalk from direct sales to a channel-partner distribution model to reduce operating expenses and accelerate long-term revenue growth, despite near-term timing gaps and a 26% increase in total operating expenses to $7.5 million.
Cash and cash equivalents increased to $4.5 million as of September 30, 2026, up from $2.2 million at year-end 2025, while the company advances its diversified biomedical strategy with the development of the Protein Oral Delivery (POD™) platform and AI-enabled rehabilitation technologies.